

Data Sharing Statement

Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2028836.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	Please submit requests to Dr. John Stone, jhstone@mgh.harvard.edu
When will data availability begin?	January 1, 2021
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	Analytic/Statistical code. Informed Consent Form. Other
Additional information about supporting documents	Statistical Analysis Plan Data Management Plan
How or where can supporting documents be obtained?	Please submit requests to Dr. John Stone, jhstone@mgh.harvard.edu
When will supporting documents availability begin?	January 1, 2021
When will supporting documents availability end?	—
To whom will data be available?	Researchers whose proposed use of the data has been approved.
For what type of analysis or purpose?	Any purpose
By what mechanism?	Following approval of proposal
Any other restrictions?	—
Additional information	—

This statement was posted on October 21, 2020, at [NEJM.org](https://www.nejm.org).